Fostamatinib was approved in 2018 to treat adults with chronic immune thrombocytopenia (ITP) who had an insufficient response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback